GGrantIndex
Sort

40,608 grants matching prostate cancer

CHAPERONE FUNCTION IN ANDROGEN-INDEPENDENT PROSTATE CANCER

$568,125
Rector & Visitors Of The University Of Virginia · · FY2009 · Department of the Army

PROSTATE CANCER METASTASIS, CELL-BONE MARROW ADHESION MEDIATORS

$568,100
Rector & Visitors Of The University Of Virginia · · FY2008 · Department of Defense

Tailored prostate cancer screening: addressing USPSTF priority research gaps in a racially-diverse study population

$567,769
Marvin Epolian Langston · Stanford University · R01 · FY2025 · CA

Image-guided TRAIL-enhanced CAR T-cell immunotherapy

$567,760
Vladimir Ponomarev · Sloan-Kettering Inst Can Research · R01 · FY2020 · CA

Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification

$567,651
Kyung Hyun Sung · University Of California Los Angeles · R01 · FY2020 · CA

Ultra-Low Count Quantitative SPECT for Alpha-Particle Therapies

$567,617
Abhinav K Jha · Washington University · R01 · FY2025 · EB

Ultra-Low Count Quantitative SPECT for Alpha-Particle Therapies

$567,617
Abhinav K Jha · Washington University · R01 · FY2024 · EB

Genetics of Prostate Cancer Susceptibility

$567,521
Fred Hutchinson Cancer Research Center · R01 · FY2002 · CA

Develop CEES-induced skin toxicity models and evaluate silibinin efficacy

$567,491
Rajesh Agarwal · National Jewish Health · U54 · FY2009 · ES

Improving Urinary Continence and Quality of Life in Prostate Cancer Patients

$567,468
Amy Y Zhang · Case Western Reserve University · R01 · FY2012 · CA

Small molecule probes of MYC stability and function intumorigenesis

$567,361
Sarki A. Abdulkadir · Northwestern University At Chicago · R01 · FY2021 · CA

Career Development in Pediatric and Medical Oncology

$567,345
Soheil Meshinchi · Fred Hutchinson Cancer Center · K12 · FY2023 · CA

RISK FACTORS FOR ADVANCED PROSTATE CANCER

$567,261
University Of Southern California · R01 · FY2002 · CA

A Personalized Digital Outreach Intervention for Lung Cancer Screening

$567,242
David P Miller · Wake Forest University Health Sciences · R01 · FY2021 · CA

A novel role for EZH2 in PARP regulation and PARPi-resistance in prostate cancer

$567,198
Qi Cao · Northwestern University At Chicago · R01 · FY2025 · CA

Enhancing Colorectal CA Screening through Learning Teams

$567,137
Benjamin F Crabtree · Univ Of Med/Dent Nj-R W Johnson Med Sch · R01 · FY2007 · CA

Mammalian Target of Rapamycin in Prostate Carcinogenesis

$567,105
Washington University · R01 · FY2005 · CA

Multidimensional analyses to improve PSMA-RPT efficacy in mCRPC

$567,087
Johannes Czernin · University Of California Los Angeles · R01 · FY2024 · CA

Genetic determinants of gene expression phenotypes in aggressive prostate cancer

$567,060
Liang Wang · Medical College Of Wisconsin · R01 · FY2013 · CA

PROMISS - Prostate Modeling to Identify Surveillance Strategies

$567,040
Ruth D Etzioni · Fred Hutchinson Cancer Research Center · R01 · FY2016 · CA

Recovery Support for Bladder CA Patients and Caregivers: A Multimodal Approach

$567,008
Michael A Diefenbach · Feinstein Institute For Medical Research · R01 · FY2022 · CA

Revisiting Antiangiogenic Therapy to Target Hormone-Sensitive Prostate Cancer Metabolism

$566,917
Daniel Edward Frigo · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA

Screening and Risk Biomarkers for Ovarian Cancer in EPIC Specimens

$566,874
Daniel William Cramer · Brigham And Women'S Hospital · R01 · FY2012 · CA

Identification of DNA methylation markers for risk of metastasis in localized pro

$566,816
Chun R. Chao · Kaiser Foundation Research Institute · R01 · FY2017 · CA

Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET

$566,741
Jason S Lewis · Sloan-Kettering Inst Can Research · R01 · FY2015 · CA